Defining treatment failure in resource-rich settings

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 459-466

  Aldous, Jeannette L ^a   Haubrich, Richard H ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV RNA; Treatment failure; Viral load; Virologic failure 'blips'

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 70350555560     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328331dea5     Document Type: Review

References (60)

1. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
2. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43:1329-1336.
3. Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIVinfected patients. AIDS 2005; 19:1081-1089.
4. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to
5. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16:615-618.
6. Ribaudo H. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold
7. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
8. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIVinfected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091-1098.
9. Haubrich RH, Currier JS, Forthal DN, et al. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis 2001; 33:1060-1068.
10. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-11112.
11. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-1511.
12. Napravnik S, Edwards D, Stewart P, et al. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40:34-40.
13. Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
14. DHHS. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008. pp. 1-139.
15. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2008; 300:555-570.
16. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71.
17. World Health Organization. Antiviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006 revision. www.who.int/hiv.
18. Stevens G, Rekhviashvili N, Scott LE, et al. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol 2005; 43:857-861.
19. Stewart P. Performance of the Cavidi ExaVir load assay and the ultra-sensitive p24 antigen assays relative to the Roche Monitor HIV-1 RNA assay: ACTG New Works Concept Sheet 227. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 2009 [Abstract 1002].
20. Relucio K, Holodniy M. HIV-1 RNA and viral load. Clin Lab Med 2002; 22:593-610.
21. Peter JB, Sevall JS. Molecular-based methods for quantifying HIV viral load. AIDS Patient Care STDS 2004; 18:75-79.
22. Holodniy M. HIV-1 load quantitation: a 17-year perspective. J Infect Dis 2006; 194 (Suppl 1):S38-S44.
23. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. J Am Med Assoc 2005; 293:817-829.
24. Rebeiro PF, Kheshti A, Bebawy SS, et al. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis 2008; 47:1354-1357.
25. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the AMPLICOR assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
26. Damond F, Roquebert B, Benard A, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/ COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007; 45:3436-3438.
27. Gueudin M, Plantier JC, Lemee V, et al. Evaluation of the Roche COBAS TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007; 44:500-505.
28. Schumacher W, Frick E, Kauselmann M, et al. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38:304-312.
29. Holodniy M. Critical issues in the treatment and management of HIV infection: review of HIV-1 viral load testing. HIVandHepatitis.com; 2005.
30. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.
31. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
32. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24- week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
33. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a phase III double-blind randomized trail to evaluate the efficacy and safety of etravirine vs. placebo in 612 treatment-experienced HIV-1 infected patients. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 2008 [Abstract 790].
34. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
35. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12:1619-1624.
36. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-1880.
37. Smith CJ, Staszewski S, Sabin CA, et al. Use of viral load measured after weeks of highly active antiretroviral therapy to predict virologic outcome at weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr 2004; 37:1155-1159.
38. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc 2001; 286:2560-2567.
39. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17:1741-1751. (Pubitemid 37000092)
40. Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248-256.
41. Ribaudo H. Factors associated with virologic failure and their impact on treatment outcomes: an analysis of virologic failure in ACTG 388. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, February 2004 [Abstract 553].
42. Aldous J, Jain S, Sun S, et al. Increasing prevalence of triple-class antiretroviral experienced patients is not associated with virologic failure: data from the CFAR Network of Integrated Clinical Systems (CNICS) Cohort. Antiviral Therapy 2009; 14 (Suppl 1):A84.
43. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. J Am Med Assoc 2001; 286:171-179.
44. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J Am Med Assoc 1999; 282:1627-1632.
45. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
46. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-531.
47. Havlir D. Are episodes of transient viremia ('blips' in HIV RNA) predictive of virologic failure in heavily treatment-experienced patients? 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 2002 [Abstract 93].
48. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained lowlevel HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-1969.
49. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 2005; 51:195-200.
50. Raboud JM, Rae S, Woods R, et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002; 16:1627-1632.
51. Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437-441.
52. Mocroft A, Phillips AN, Miller V, et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS 2001; 15:201-209.
53. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
54. Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis 2008; 197 (Suppl 3):S261-S271.
55. Tenorio AR, Smith KY, Kuritzkes DR, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003; 34:491-496.
56. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4- positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
57. Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr 2004; 37:1147-1154.
58. Olsen CH, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIVRNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.
59. Pillay D. HIV viral load: the myth of the undetectable? Rev Med Virol 2002; 12:391-396.
60. Phillips AN, Walker AS. Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18:365-370.